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Summary
Background Varenicline is an eﬀ ective pharmacotherapy to aid smoking cessation. However, its use is limited by 
continuing concerns about possible associated risks of serious adverse cardiovascular and neuropsychiatric events. 
The aim of this study was to investigate whether use of varenicline is associated with such events.
Methods In this retrospective cohort study, we used data from patients included in the validated QResearch database, 
which holds data from 753 National Health Service general practices across England. We identiﬁ ed patients aged 
18–100 years (registered for longer than 12 months before data extraction) who received a prescription of nicotine 
replacement treatment (NRT; reference group), bupropion, or varenicline. We excluded patients if they had used one 
of the drugs during the 12 months before the start date of the study, had received a prescription of a combination of 
these drugs during the follow-up period, or were temporary residents. We followed patients up for 6 months to 
compare incident cardiovascular (ischaemic heart disease, cerebral infarction, heart failure, peripheral vascular 
disease, and cardiac arrhythmia) and neuropsychiatric (depression and self-harm) events using Cox proportional 
hazards models, adjusted for potential confounders (primary outcomes).
Findings We identiﬁ ed 164 766 patients who received a prescription (106 759 for nicotine replacement treatment; 
6557 for bupropion; 51 450 for varenicline) between Jan 1, 2007, and June 30, 2012. Neither bupropion nor varenicline 
showed an increased risk of any cardiovascular or neuropsychiatric event compared with NRT (all hazard ratios [HRs] 
less than 1). Varenicline was associated with a signiﬁ cantly reduced risk of ischaemic heart disease (HR 0·80 [95% CI 
0·72–0·87]), cerebral infarction (0·62 [0·52–0·73]), heart failure (0·61 [0·45–0·83]), arrhythmia (0·73 [0·60–0·88]), 
depression (0·66 [0·63–0·69]), and self-harm (0·56 [0·46–0·68]).
Interpretation Varenicline does not seem to be associated with an increased risk of documented cardiovascular events, 
depression, or self-harm when compared with NRT. Adverse events that do not come to attention of general 
practitioners cannot be excluded. These ﬁ ndings suggest an opportunity for physicians to prescribe varenicline more 
broadly, even for patients with comorbidities, thereby helping more smokers to quit successfully than do at present.
Funding Egton Medical Information Systems, University of Nottingham, Ministry of Innovation, Science and 
Research of the German Federal State of North Rhine-Westphalia, Cancer Research UK, Medical Research Council, 
Commonwealth Fund.
Copyright © Kotz et al. Open Access article published under the terms of CC BY.
Introduction
Cigarette smoking continues to be one of the leading 
causes of preventable death, killing nearly 6 million 
people worldwide each year.1 Smokers who do not stop 
lose, on average, a decade of life expectancy.2 Eﬀ ective 
pharmacotherapies to help smokers quit include 
bupropion, nicotine replacement treatment (NRT), and 
varenicline.3–5 Varenicline, a selective α4β2 nicotine 
acetylcholine receptor partial agonist, was approved by 
the US Food and Drug Administration (FDA) and 
European Medicines Agency as a drug for smoking 
cessation in 2006, and it has subsequently been 
recommended by US6 and international7,8 clinical 
guidelines.6–8 Varenicline is more eﬀ ective than are 
bupropion5,9–11 and single forms of NRT,9,12,13 and it has 
become the most frequently prescribed smoking 
cessation drug other than NRT.14 It is also eﬀ ective and 
safe in increasing long-term smoking cessation rates via 
smoking reduction in cigarette smokers not willing or 
able to quit at treatment initiation.15
The safety proﬁ le of varenicline was initially established 
with standard approaches to pharmaco vigilance. 
However, subsequent postmarketing reports raised 
concerns about the risk of serious adverse cardiovascular 
and neuropsychiatric events. Authors of a meta-analysis16 
reported an increased risk of cardio vascular events in 
varenicline users. Although this study had some major 
limitations,17 and later meta-analyses did not ﬁ nd a 
signiﬁ cant association,9,18 cardiovascular events have 
been included by the FDA as a warning in the drug’s 
prescribing information.19 Possible mechanisms for 
increased cardiovascular risk could relate to varenicline’s 
action on α3β4 receptors in the peripheral ganglia and 
subsequent release of acetylcholine and catecholamines, 
and the central eﬀ ect of α4β2 and α7 nicotinic 
acetylcholine receptors on blood pressure homoeostasis.20
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Neuropsychiatric events in varenicline users might, in 
part, be attributable to smoking itself—ie, to neuro-
psychiatric disorders that already existed before the quit 
attempt or to other smoking-related disorders that are 
themselves associated with increased neuropsychiatric 
risk.21,22 Nevertheless, the FDA and European Medicines 
Agency issued warnings that serious neuropsychiatric 
symptoms had occurred in smokers trying to quit with 
varenicline, consisting of changes in behaviour, agitation, 
depressed mood, suicidal ideation, and attempted and 
completed suicides.23,24 Moreover, the FDA judged the 
events identiﬁ ed by the postmarketing reports to be 
suﬃ  ciently indicative of a causal association with the 
drug to include a black box warning about neuro-
psychiatric events.
A meta-analysis18 of clinical trials, and observational 
studies25–30 carried out in general smoking populations, 
did not ﬁ nd any increased risk of cardiovascular or 
neuropsychiatric events in varenicline users. However, 
this evidence has not been deemed suﬃ  cient by the FDA 
to remove the black box warning or change the label 
warning.31 Previous randomised controlled trials, even 
when analysed in combination, had limited power to 
detect rare, serious adverse events, and might have 
excluded patients who would be most susceptible to 
experiencing them (because patients need to provide 
informed consent, and selection of patients occurs 
through exclusion criteria, resulting in a population that 
is healthier and less vulnerable than the general 
population is). Results from previous observational 
studies have been criticised by the FDA as being biased 
by residual confounding.31
The aims of this study were therefore to investigate the 
most important cardiovascular and neuropsychiatric 
adverse events with use of one of the largest validated 
databases and assess and reduce the risk of confounding 
further than any previous study has. Our work extends 
previous studies by being, to our knowledge, the largest 
study ever done on this topic with use of a general 
practice dataset in a country (England) with a national 
health-care system in which all members of the 
community, irrespective of socioeconomic status, had 
free and ready access to smoking cessation treatment. To 
our knowledge, we are the ﬁ rst to include both neuro-
psychiatric and cardiovascular adverse events in one and 
the same study and model what the distribution and 
eﬀ ect of unmeasured confounders would need to be for 
the key conclusions to be incorrect.
Methods
Study design and patients
In this national, retrospective cohort study, we used the 
QResearch database (version 36, upload July 31, 2013), 
which holds anonymised health records for more than 
13 million patients from 753 National Health Service 
general practices from across England. The database has 
been used for various studies before, including those of 
the incidence and risk of neuropsychiatric32 and cardio-
vascular33–36 events. Findings from external validation 
studies showed that studies using this database yield 
similar results to those using other databases, such as 
the Clinical Practice Research Datalink37,38 and Health 
Improvement Network databases.39 The study protocol 
has been published elsewhere.40 The only deviation from 
Research in context
Evidence before this study
We searched PubMed and the Food and Drug Administration 
website for relevant reports, and the reference lists of the 
identiﬁ ed reports. Authors of one meta-analysis reported a small 
but signiﬁ cantly increased risk of a composite of cardiovascular 
events in varenicline users, but authors of two later meta-
analyses did not. Investigators of a retrospective cohort study 
with use of a Danish patient registry noted neither a signiﬁ cant 
increase in a composite of cardiovascular events nor an increase 
in acute coronary syndrome, ischaemic stroke, or cardiovascular 
death. Investigators of two retrospective cohort studies with use 
of data from a UK general practice database did not ﬁ nd an 
increased risk of depression, suicidal thoughts, or self-harm in 
varenicline compared with nicotine replacement treatment (NRT) 
users. Investigators of a retrospective cohort study with use of a 
US military health system claims database did not ﬁ nd an increase 
in the proportion of neuropsychiatric admissions to hospital in 
patients given varenicline compared with NRT patches.
Added value of this study
This study is, to our knowledge, the largest study ever done on 
this topic. It uses a validated general practice dataset in a 
country (England) with a national health-care system in which 
all members of the community have free and ready access to 
smoking cessation treatment. It includes, to our knowledge for 
the ﬁ rst time, the most important neuropsychiatric and 
cardiovascular adverse events in one and the same study. It uses 
propensity score matching and regression modelling to take 
maximum account of confounding. Finally, it models what 
would need to be the distribution and eﬀ ect of unmeasured 
confounders for the key conclusions to be incorrect.
Implications of all the available evidence
The ﬁ ndings from our study substantiate the results of meta-
analyses and previous small observational studies that show 
that varenicline is not likely to increase the risk of self-harm or 
depression or any of a wide range of cardiovascular outcomes. 
Although this study could not rule out adverse reactions that 
do not get recorded in general practice records, the ﬁ ndings 
have clear implications for the safety warnings for varenicline 
and for clinical practice. They suggest an opportunity for 
physicians to prescribe varenicline more broadly, even for 
patients with comorbidities, thereby helping more smokers to 
quit successfully than do at present. 
For the QResearch database see 
www.qresearch.org
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our published plan is that we could not do an instrumental 
variable analysis because we were unable to identify a 
valid instrumental variable, so we instead did additional 
analyses (ie, modelling) to assess the eﬀ ect of any 
potential unmeasured confounding. Use of this partic-
ular method was also prompted by concerns raised by 
the FDA in relation to evidence from previous 
observational studies of the safety of varenicline.31
We studied adult patients aged 18–100 years (registered 
for longer than 12 months before data extraction) who 
received prescriptions for varenicline, bupropion, or NRT 
between Jan 1, 2007, and June 30, 2012. The date of ﬁ rst 
prescription of one of these drugs deﬁ ned the individual’s 
entry date to the cohort. We excluded patients if they had 
used one of the drugs during the 12 months before the 
start date of the study (ie, between Jan 1, 2006, and Dec 31, 
2006) or received a prescription of a combination of these 
drugs during the 6 month follow-up period. We also 
excluded those who were temporary residents. 
Our protocol was independently peer reviewed by the 
QResearch Scientiﬁ c Board and satisﬁ ed the require-
ments of the Trent Research Ethics Committee.
Procedures
We classiﬁ ed patients into three exposure groups—
varenicline alone, bupropion alone, or NRT alone (used 
as a reference group because it is presumed by regulators 
not to carry serious risks)—on the basis of the drug that 
they were ﬁ rst prescribed. In the UK, all three drugs are 
only licensed for use to help smoking cessation. Start of 
follow-up began for each patient on the date of the ﬁ rst 
prescription and ended after 6 months of follow-up or 
when reaching the speciﬁ c event of interest. We censored 
patients who were lost to follow-up because they left the 
practice or died. 
Outcomes
We separately considered major incident neuropsychiatric 
and cardiovascular events that occurred during 6 months 
of follow-up (on the basis of appropriate Read codes—a 
coding system used by general practitioners in the UK) 
for which a potential association with varenicline use has 
been suggested (primary outcomes).16,25,26 The cardio-
vascular events of interest were ischaemic heart disease 
(including myocardial infarction and angina), cerebral 
infarction and haemorrhage, heart failure, peripheral 
vascular disease, and cardiac arrhythmia (including 
cardiac arrest). The neuro psychiatric outcomes of interest 
were depression and fatal or non-fatal intentional self-
harm. A follow-up period of 6 months covers the 
treatment duration of the drugs (typically 12 weeks) and 
an extended period after treatment is stopped in which 
many of the spontaneously reported adverse events 
occurred and the excess in cardiovascular events was 
noted in meta-analyses of clinical trials. As a secondary 
outcome, we assessed occurrence of these events during 
the ﬁ rst 3 months of follow-up.
Figure: Flow chart
NRT=nicotine replacement treatment. PS=propensity score. 
7 272 681 patients assessed for eligibility
7 107 790 ineligible
164 891  using NRT, bupropion, or varenicline
125 no data on 
socioeconomic status
164 766 enrolled
6557 using bupropion 
in Cox regression 
analysis
106 759 using NRT in 
Cox regression 
analysis
51 450 using varenicline 
in Cox regression 
analysis
164 no match with 
patients using 
NRT
1287 no match with 
patients using 
NRT
6393 using bupropion 
in PS analysis
6393 using NRT in  
PS analysis
50 163 using varenicline 
               in PS analysis
50 163 using NRT in 
               PS analysis
1:1
match
1:1
match
NRT
(n=106 759)
Bupropion 
(n=6557)
Varenicline 
(n=51 450)
Age (years) 40·4 (13·6) 37·7 (11·1) 38·1 (11·5)
Female sex 55 345 (52%) 3172 (48%) 24 686 (48%)
Socioeconomic status* 3·2 (1·4) 2·9 (1·3) 3·0 (1·3)
Chronic obstructive pulmonary disease 12 112 (11%) 427 (7%) 4140 (8%)
Diabetes 7415 (7%) 229 (3%) 2511 (5%)
Peptic ulcer disease 3334 (3%) 136 (2%) 1243 (2%)
Renal disease 4618 (4%) 170 (3%) 1457 (3%)
Rheumatological disease 3001 (3%) 106 (2%) 1059 (2%)
Cancer 4311 (4%) 159 (2%) 1449 (3%)
Alcohol misuse 8713 (8%) 321 (5%) 2932 (6%)
Previous ischaemic heart disease 6098 (6%) 175 (3%) 1791 (3%)
Previous cerebral infarction 3477 (3%) 97 (1%) 852 (2%)
Previous heart failure 854 (1%) 19 (<1%) 186 (<1%)
Previous peripheral vascular disease 1354 (1%) 42 (1%) 412 (1%)
Previous arrhythmia 2335 (2%) 85 (1%) 659 (1%)
Previous depression 40 255 (38%) 2215 (34%) 16 242 (32%)
Previous self-harm 12 043 (11%) 610 (9%) 4621 (9%)
Data are mean (SD) or n (%). NRT=nicotine replacement treatment. *Townsend Index: 1 (lowest level of deprivation) 
to 5 (highest level of deprivation).41
Table 1: Baseline characteristics 
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Statistical analysis
We used Cox proportional hazards regression models to 
assess the association between exposure group and each 
of the events, adjusted for all measured potential con-
founders. We included the following variables, measured 
at or before the patient’s entry date to the cohort, in the 
analyses as potential confounders: age, sex, 
socioeconomic status (measured with the Townsend 
Index41), Strategic Health Authority of the general 
practice, relevant comorbidities from the Charlson 
Index42 (ie, chronic obstructive pulmonary disease, 
diabetes, peptic ulcer disease, renal disease, rheumatol-
ogical disease, or cancer), and alcohol misuse. 
Additionally, we included any recordings of the 
neuropsychiatric and cardiovascular events of interest 
that occurred before the patient’s entry date to the 
cohort.
We entered all variables into the models as binary 
variables except for the continuous variables age and 
socioeconomic status. We used a propensity score 
analysis with trimming  and matching to account for 
potential confounding by indication.40 Additionally, we 
used an approach described by Lin and colleagues43 to 
model the eﬀ ects of any potential unmeasured con-
founding. To this end, we adjusted the hazard ratios 
(HRs) and 95% CIs in varenicline versus NRT users for 
each of the events for a hypothetical, unmeasured, 
binary confounder, with an HR of 3 and various 
combinations of prevalence in the two exposure 
groups.
We did all analyses in R (version 3.0.2 or later). We 
provide the codes used in R in the appendix. All statistical 
tests were two-sided, with p<0·05 showing signiﬁ cance.
Role of the funding source
The funder of the study provided access to the 
QResearch database, which included collection and 
management of data. The funder of the study had no 
role in study design, data analysis, data interpretation, 
or writing of the report. The corresponding author had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
We identiﬁ ed 164 766 patients who received prescriptions 
between Jan 1, 2007, and June 30, 2012, and included 
them in the analyses: 106 759 NRT users, 6557 bupropion 
users, and 51 450 varenicline users (ﬁ gure). A few 
patients (125 [<1%] of 164 891 patients using NRT, 
bupropion, or varenicline) had missing data on the 
measure of socioeconomic status and we therefore 
excluded them. NRT users were older and more 
socioeconomically deprived than were bupropion and 
varenicline users, and showed a higher prevalence of all 
confounding factors (table 1). We noted the highest 
incidence of events for depression and ischaemic heart 
disease (table 2, appendix).
Neither bupropion nor varenicline showed an increased 
risk of any cardiovascular or neuropsychiatric event 
compared with NRT (all HRs less than 1·00; primary 
outcomes; table 2). Rather, varenicline was associated 
with a signiﬁ cantly reduced risk of ischaemic heart 
disease (HR 0·80 [95% CI 0·72–0·87), cerebral infarction 
Patient-
years
Number of 
events
Incidence of event 
per 1000 patient-
years
Hazard ratio
Crude Adjusted
Ischaemic heart disease
NRT 52 289 2148 41·1 1 1
Bupropion 3246 52 16·0 0·39 (0·30–0·51) 0·67 (0·51–0·89)
Varenicline 25428 594 23·4 0·57 (0·52–0·62) 0·80 (0·72–0·87)
Cerebral infarction
NRT 52 705 871 16·5 1 1
Bupropion 3259 18 5·5 0·33 (0·21–0·53) 0·55 (0·35–0·89)
Varenicline 25 557 164 6·4 0·39 (0·33–0·46) 0·62 (0·52–0·73)
Heart failure
NRT 52 895 302 5·7 1 1
Bupropion 3262 7 2·1 0·38 (0·18–0·80) 0·71 (0·33–1·51)
Varenicline 25 588 52 2·0 0·36 (0·27–0·48) 0·61 (0·45–0·83)
Peripheral vascular disease
NRT 52 849 430 8·1 1 1
Bupropion 3259 14 4·3 0·53 (0·31–0·90) 0·83 (0·48–1·41)
Varenicline 25 563 123 4·8 0·59 (0·48–0·72) 0·82 (0·67–1·01)
Arrhythmia
NRT 52 815 563 10·7 1 1
Bupropion 3260 14 4·3 0·40 (0·24–0·69) 0·66 (0·39–1·13)
Varenicline 25 561 126 4·9 0·46 (0·38–0·56) 0·73 (0·60–0·88)
Depression
NRT 50 558 8274 163·7 1 1
Bupropion 3162 357 112·9 0·69 (0·62–0·77) 0·75 (0·67–0·83)
Varenicline 24 965 2395 95·9 0·59 (0·56–0·61) 0·66 (0·63–0·69)
Self-harm
NRT 52 832 540 10·2 1 1
Bupropion 3259 20 6·1 0·60 (0·38–0·94) 0·74 (0·48–1·16)
Varenicline 25 570 119 4·7 0·46 (0·37–0·56) 0·56 (0·46–0·68)
Data in parentheses are 95% CIs. NRT=nicotine replacement treatment. 
Table 2: Incidence of events and hazard ratios of drug groups for all events during 6 month follow-up
Bupropion vs NRT (n=12 786) Varenicline vs NRT (n=100 326)
Ischaemic heart disease 0·59 (0·37–0·93) 0·86 (0·76–0·97)
Cerebral infarction 0·46 (0·24–0·89) 0·58 (0·47–0·73)
Heart failure 0·44 (0·14–1·44) 0·64 (0·42–0·98)
Peripheral vascular disease 1·62 (0·67–3·92) 0·95 (0·73–1·23)
Arrhythmia 0·43 (0·21–0·91) 0·72 (0·55–0·92)
Depression 0·80 (0·70–0·92) 0·65 (0·61–0·68)
Self-harm 0·90 (0·49–1·68) 0·60 (0·48–0·76)
Data in parentheses are 95% CIs. NRT=nicotine replacement treatment.
Table 3: Hazard ratios of events during 6 months follow-up in the propensity score matched samples
See Online for appendix
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(0·62 [0·52–0·73]), heart failure (0·61 [95% CI 0·45–0·83]), 
arrhythmia (0·73 [95% CI 0·60–0·88]), depression (0·66 
[0·63–0·69]), and self-harm (0·56 [0·46–0·68]).
χ² tests showed that hazards were not proportional for 
the outcomes of ischaemic heart disease (p<0·0001), 
cerebral infarction (p=0·004), and depression 
(p<0·0001), but a ﬁ ne-grained analysis allowing for 
varying HRs showed that HRs were always less than 1 
across the entire follow-up period for the three outcomes. 
Thus, for these three outcomes, the reported HRs can be 
regarded as an average across the follow-up period. 
Furthermore, we noted that the risk of arrhythmia 
(p=0·02) and depression (p<0·0001) in varenicline users 
compared with NRT diﬀ ered signiﬁ cantly between 
women and men, but the HRs were again always less 
than 1. 
After trimming and matching of patients by propensity 
score, the sample size was 12 786 for the comparison of 
bupropion with NRT, and 100 326 for that of varenicline 
with NRT (ﬁ gure, appendix). Neither bupropion nor 
varenicline showed any evidence of increased risk of any 
neuropsychiatric or cardiovascular event compared with 
NRT (table 3).
The modelling of unmeasured confounding showed 
that an increased risk of any of the neuropsychiatric and 
cardiovascular events assessed in varenicline users was 
very unlikely (appendix). For example, an unmeasured 
confounder with an HR of 3 for self-harm would have 
reversed the noted reduced HR in varenicline users 
versus NRT, making it an increased HR, only if this 
confounder had been distributed very diﬀ erently in the 
two exposure groups. For such an outcome, the 
prevalence of this confounder would need to be only 10% 
in varenicline users and simultaneously be noted in at 
least 80% of NRT users (table 4).
Cox proportional hazards regression and propensity 
score analyses and modelling of unmeasured 
confounding with the occurrence of the cardiovascular 
and neuropsychiatric events during 3 months of follow-
up yielded very similar results (secondary outcomes; 
appendix).
Discussion
We noted no evidence of any increased risk of cardio-
vascular or neuropsychiatric adverse events in smokers 
using varenicline or bupropion when compared with 
NRT users. On the contrary, some events were associated 
with a reduced risk, including the events with the highest 
noted incidences (ie, depression and ischaemic heart 
disease). We noted that modelling of the eﬀ ects of any 
potential unmeasured confounders showed that a 
confounder would only lead to an increased risk 
associated with varenicline use under unlikely 
assumptions.
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(0·54–0·8)
0·71
(0·59–0·87)
0·76
(0·63–0·93)
0·7 0·23
(0·19–0·28)
0·28
(0·23–0·34)
0·33
(0·27–0·4)
0·37
(0·31–0·45)
0·42
(0·35–0·51)
0·47
(0·38–0·57)
0·51
(0·42–0·62)
0·56
(0·46–0·68)
0·61
(0·5–0·74)
0·65
(0·54–0·79)
0·7
(0·58–0·85)
0·8 0·22
(0·18–0·26)
0·26
(0·21–0·31)
0·3
(0·25–0·37)
0·34
(0·28–0·42)
0·39
(0·32–0·47)
0·43
(0·35–0·52)
0·47
(0·39–0·58)
0·52
(0·42–0·63)
0·56
(0·46–0·68)
0·6
(0·5–0·73)
0·65
(0·53–0·78)
0·9 0·2
(0·16–0·24)
0·24
(0·2–0·29)
0·28
(0·23–0·34)
0·32
(0·26–0·39)
0·36
(0·3–0·44)
0·4
(0·33–0·49)
0·44
(0·36–0·53)
0·48
(0·39–0·58)
0·52
(0·43–0·63)
0·56
(0·46–0·68)
0·6
(0·49–0·73)
1·0 0·19
(0·15–0·23)
0·22
(0·18–0·27)
0·26
(0·21–0·32)
0·3
(0·25–0·36)
0·34
(0·28–0·41)
0·37
(0·31–0·45)
0·41
(0·34–0·5)
0·45
(0·37–0·54)
0·49
(0·4–0·59)
0·52
(0·43–0·63)
0·56
(0·46–0·68)
This table shows how the noted hazard ratio (in the central diagonal line of cells) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and diﬀ erent combinations of prevalences in 
user groups. P1 and P0 are the prevalences of the unmeasured confounder in varenicline (P1) and NRT (P0) users. Data in parentheses are 95% CIs. NRT=nicotine replacement treatment. *Varenicline would be 
associated with a signiﬁ cantly increased hazard of the event. †The hazard would also be clinically meaningful according to our study protocol (hazard ratio of 1·5 or higher).
Table 4: Hazard ratio for self-harm during 6 months’ follow-up in varenicline versus NRT users, adjusted for an unmeasured binary confounder with a hazard ratio of 343
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Authors of one meta-analysis16 reported a small but 
signiﬁ cant increased risk of serious adverse cardio-
vascular events in varenicline users, whereas authors of 
two more meta-analyses9,18 and a network meta-analysis44 
did not ﬁ nd an increase in such events. Rapid assessment 
of cardiovascular outcomes within the FDA’s Mini-
Sentinel programme showed no consistent evidence of 
increased cardiovascular risk with varenicline.45
Authors of systematic reviews and meta-analyses did 
not ﬁ nd evidence for an increased risk of serious adverse 
neuropsychiatric events in varenicline users.9,46,47 Authors 
of two studies26,27 with use of data from a UK general 
practice database similar to the one that we used noted 
no association between varenicline use and increased 
risk of depression, suicidal thoughts, or self-harm. In 
fact, the authors of one of the studies27 noted a 
signiﬁ cantly reduced risk of depression in varenicline 
(HR 0·75 [95% CI 0·65–0·87]) and bupropion (0·63 
[95% CI 0·46–0·87]) users in comparison with NRT; the 
estimated HRs are similar to ours (but with less 
precision). Investigators of no other cohort studies28–30 
noted an association between use of varenicline and 
neuropsychiatric events.
A striking ﬁ nding in our study was the diﬀ erence 
between patient characteristics at baseline. Compared 
with bupropion and varenicline users (who had very 
similar characteristics), NRT users were older and more 
socioeconomically deprived, and showed a higher 
prevalence of all of the cardiovascular and neuro-
psychiatric risk factors and comorbid diseases. In the 
statistical models used for our analyses, however, these 
diﬀ erences were balanced. Investigators of only a few 
previous observational studies compared NRT with 
varenicline or bupropion users. Investigators of one 
study,28 done in the US military health system database, 
did not ﬁ nd a diﬀ erence in previous neuropsychiatric 
disease between NRT and varenicline users, whereas 
investigators of two other studies,26,27 both done in the 
same English general practice database, noted that users 
of NRT were more likely to have had previous psychiatric 
events and chronic illness, misuse alcohol, and use 
hypnotics, antipsychotics, and antidepressants. Thus, 
varenicline and bupropion seem currently less likely to 
be prescribed to smokers in general practice with 
smoking-related illnesses and comorbidities.
Our study has several limitations, most of which are 
related to the observational study design. In view of the 
potential importance of unmeasured confounders in 
observational studies and the large diﬀ erence in 
measured confounders between those receiving pre-
scriptions for NRT and those receiving them for 
bupropion or varenicline, we set out, to our knowledge 
for the ﬁ rst time, to model whether such confounders 
could reasonably reverse the study conclusions. We set 
the combined HR of unmeasured confounders at 3. This 
HR can be viewed as conservative in the sense that it 
allows the unmeasured confounders to have a very strong 
eﬀ ect (eg, an HR of 3 is equivalent to the increased risk of 
premature death for present vs never smokers2). Also, 
except for previous occurrences of the speciﬁ c event of 
interest, none of the noted confounders had an HR as 
high as 3 in any of the analyses (data not shown). Even so, 
our results show that the noted reduced risk of 
neuropsychiatric and cardiovascular events in varenicline 
versus NRT users could only be reversed, making it an 
increased risk, if a composite of the unmeasured 
confounders was distributed very diﬀ erently in the 
exposure groups. For any of the events, the prevalence of 
the unmeasured confounders would need to be at least 
20% higher in the NRT group than in the varenicline 
group for the conclusions to be false (appendix; or 50% 
higher to generate an HR of 1·5 or higher in varenicline 
users, a relative hazard that we established as clinically 
meaningful in our study protocol40). None of the noted 
confounders were distributed so unevenly between the 
two groups; the most unevenly distributed confounder 
was previous depression, with a prevalence of 38% in 
NRT versus 32% in varenicline users (table 1). Thus, our 
ﬁ ndings are unlikely to be confounded to an extent that 
would have obscured an increased risk of varenicline. 
However, the modelling approach as applied has a 
limitation as well: it assumes that the unmeasured 
confounder is not associated with other confounders 
within the exposure group.43
A second limitation is that our analyses relied on 
routinely collected data. Some data might have been 
incomplete or inaccurate; however, we believe that 
incomplete or inaccurate data are unlikely in light of the 
fact that the QResearch database has been validated for 
answering research questions such as ours.40 In most 
UK general practices, the electronic health record is the 
only patient record. It is therefore populated mainly for 
use as a clinical rather than billing record—in many 
parts of the USA, for example, its main use is as a 
billing record. Some variables of potential interest were 
not available, including drug adherence or potential 
confounders such as previous or present levels of 
tobacco exposure. For drug adherence, we used general 
practitioner prescription data, which could overestimate 
drug exposure because not all patients collect their 
drugs, and those who do do not always adhere to the 
prescribed dosing schedule. However, this factor would 
have biased our results only in the case of systematic 
diﬀ erences in drug adherence between the three drugs 
being studied. Tobacco exposure might be a confounding 
factor because it is a risk factor for cardiovascular or 
neuropsychiatric events and might be associated with 
type of smoking cessation drug.48 We attempted to 
address this issue by including previous cardiovascular 
and neuropsychiatric events and a range of other 
smoking-related diseases, recorded at baseline, as 
potential confounders in our models. However, we had 
no data for smoking cessation during follow-up to 
assess potential diﬀ erences in eﬀ ectiveness of the three 
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drugs. Thus, we were unable to fully disentangle the 
complex pathways between type of drug, serious adverse 
events being studied, and mediating factors of drug 
adherence and eﬀ ectiveness in terms of smoking 
cessation.
We did not measure what the FDA has described as 
“nuanced” neuropsychiatric symptoms that are diﬃ  cult 
to classify or that involve aggression.49 Such symptoms 
probably cannot be addressed with patient records and 
need speciﬁ c monitoring in very large randomised 
controlled trials and observational studies with primary 
data collection; doubt exists as to whether such studies 
will ever prove feasible. Nevertheless, the neuropsychiatric 
symptoms that we used have been identiﬁ ed as some of 
the most important and are included in the FDA’s boxed 
warning for varenicline, and the high proportion of 
serious events noted in our study suggests that events of 
this kind would be unlikely to have not been recorded in 
the database. Furthermore, in view of the nature of the 
UK health system, with access to general practitioners 
being free of charge and, furthermore, them acting as co-
ordinators of care, these events are, we believe, very 
unlikely to be substantially under-recorded. Moreover, 
under-recording would have only introduced bias if it 
occurred systematically diﬀ erently between the three 
drugs; we have no reason to assume that this systematic 
diﬀ erence occurred. A ﬁ nal limitation is that we did not 
link our dataset to other datasets to assess mortality 
because fatalities would usually be recorded in this 
general practitioner dataset within a month.
A major strength of this study is that it is, to our 
knowledge, the largest original study ever done on this 
topic. Second, we investigated, with the same methods, 
ﬁ ve separate cardiovascular and two neuropsychiatric 
events in one study, of which one—peripheral vascular 
disease—has not been investigated before, with other 
cardiovascular events only having been included in meta-
analyses as composite outcomes.16,18 Third, a major 
advantage of use of a large general practice database is 
generalisability of ﬁ ndings compared with randomised 
controlled trials because almost all individuals living in 
the UK are registered with a general practice and have free 
and ready access to smoking cessation treatment, 
irrespective of their socioeconomic status. A ﬁ nal strength 
is that we published our protocol in a peer-reviewed 
journal before we began the analysis.40
In this study, we have shown that use of varenicline is 
very unlikely to be associated with an increased risk of the 
measured cardiovascular or neuropsychiatric events com-
pared with NRT. Although we cannot rule out adverse 
reactions that do not get recorded in general practice ﬁ les, 
the ﬁ ndings from this study have clear implications for the 
safety warnings for varenicline and for clinical practice. To 
not prescribe the most eﬀ ective smoking cessation drug 
on any given occasion is likely to lead to substantial loss of 
life expectancy, even if the patient stops later in life because 
patients lose, on average, 3 months of life expectancy for 
each year of continued smoking.50 Our ﬁ ndings suggest an 
opportunity for physicians to prescribe varenicline more 
broadly, even for patients with comorbidities, and thereby 
help more smokers to quit successfully than do at present.
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